Pfizer Inc. failed to convince advisers to the US Food and Drug Administration to support a dramatic expansion in the use of its prostate cancer drug, a setback ... approval of Talzenna, a pill ...

CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

Among Pfizer's precision oncology products, revenues for Ibrance (palbociclib), a CDK4/6 inhibitor used to treat hormone receptor (HR)-positive and HER2-negative breast cancer that is Pfizer's ...

The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in ...

In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to ...

Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

However, Pfizer could hold off on the acquisitions front to see how its obesity drug PF-07976016 fares in clinical testing. The market for obesity drugs presents one of the most lucrative targets ...